Progesterone for the luteal support of assisted reproductive technologies: Clinical options

Human Reproduction

Volumn 15, Issue SUPPL. 1, 2000, Pages 129-148

  Posaci, Cemal ^a,b   Smitz, Johan ^a   Camus, Michel ^a   Osmanagaoglu, Kaan ^a   Devroey, Paul ^a  

^a CENTRE FOR REPRODUCTIVE MEDICINE   (Belgium)

^b DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

ART; Luteal support; Progesterone; Route of administration

Indexed keywords

4 AMINOBUTYRIC ACID; CHLORMADINONE ACETATE; CHORIONIC GONADOTROPIN; CYPROTERONE ACETATE; DESOGESTREL; DYDROGESTERONE; ETYNODIOL DIACETATE; GESTODENE; HYDROXYPROGESTERONE CAPROATE; HYDROXYPROGESTERONE HEPTANOATE; LEVONORGESTREL; LYNESTRENOL; MEDROGESTONE; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; NORETHISTERONE ACETATE; NORGESTIMATE; NORGESTREL; PROGESTERONE; PROGESTERONE DERIVATIVE; UNCLASSIFIED DRUG;

ABSCESS; CORPUS LUTEUM FUNCTION; DEPRESSION; DRUG BIOAVAILABILITY; DYSPAREUNIA; FAINTNESS; FATIGUE; FIRST PASS EFFECT; HEADACHE; HUMAN; HYPNOSIS; INFERTILITY THERAPY; INJECTION PAIN; MOOD; OVARY HYPERSTIMULATION; REVIEW; SEDATION; TERATOGENICITY; VAGINA DISEASE; VERTIGO;

FALLOPIA;

EID: 0034047050     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/15.suppl_1.129     Document Type: Review

References (90)

1. Albano, C., Smitz, J., Camus, M. et al. (1996) Hormonal profile during the follicular phase in cycles stimulated with a combination of human menopausal gonadotrophin and gonadotrophin-releasing hormone antagonist (Cetrorelix). Hum. Reprod., 11, 2114-2118.
2. Albano, C., Smitz, J., Camus, M. et al. (1997) Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil. Steril., 67, 917-922.
3. Albano, C., Grimbizis, G., Smitz, J. et al. (1998) The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix. Fertil. Steril., 70, 357-359.
4. Andrew, F.D. and Staples, R.E. (1977) Prenatal toxicity of medroxyprogesterone acetate in rabbits, rats, and mice. Teratology, 15, 25-32.
5. Anthony, F.W., Smith, E.M., Gadd, S.C. et al. (1993) Placental protein 14 secretion during in vitro fertilization cycles with and without human chorionic gonadotropin for luteal support. Fertil. Steril., 59, 187-191.
6. Arafat, E.S., Hargrove, J.T., Maxson, W.S. et al. (1988) Sedative and hypnotic effects of oral administration of micronized progesterone may be mediated through its metabolites. Am. J. Obstet. Gynecol., 159, 1203-1209.
7. Araujo, E. Jr, Bernardini, L., Frederick, J.L. et al. (1994) Prospective randomized comparison of human chorionic gonadotropin versus intramuscular progesterone for luteal-phase support in assisted reproduction. J. Assist. Reprod. Genet., 11, 74-78.
8. Archer, D.F, Fahy, G.E., Viniegra-Sibal, A. et al. (1995) Initial and steady-state pharmacokinetics of a vaginally administered formulation of progesterone. Am. J. Obstet. Gynecol., 173, 471-477.
9. Beier, H.M. and Beier-Hellwig, K. (1998) Molecular and cellular aspects of endometrial receptivity. Hum. Reprod. Update, 4, 448-458.
10. Ben-Nun, I., Ghetler, Y., Jaffe, R. et al. (1990) Effect of preovulatory progesterone administration on the endometrial maturation and implantation rate after in vitro fertilization and embryo transfer. Fertil. Steril., 53, 276-281.
11. Belaisch-Allart, J., Testart, J, Fries, N. et al. (1987) The effect of dydrogesterone supplementation in an IVF programme. Hum. Reprod., 2, 183-185.
12. Belaisch-Allart, J., De Mouzon, J., Lapousterle, C. et al. (1990) The effect of HCG supplementation after combined GnRH agonist/HMG treatment in an IVF programme. Hum. Reprod., 5, 163-166.
13. Bourgain, C., Devroey, P., Van Waesberghe, L. et al. (1990) Effects of natural progesterone on the morphology of the endometrium in patients with primary ovarian failure. Hum. Reprod., 5, 537-543.
14. Bourgain, C., Smitz, J., Camus, M. et al. (1994) Human endometrial maturation is markedly improved after luteal supplementation of gonadotrophin-releasing hormone analogue/human menopausal gonadotrophin-stimulated cycles. Hum. Reprod., 9, 32-40.
15. Bulletti, C., Prefetto, R.A., Bazzocchi, G. et al. (1993) Electromechanical activities of human uteri during extra-corporeal perfusion with ovarian steroids. Hum. Reprod., 8, 1558-1563.
16. Bulletti, C., de Ziegler, D., Flamigni, C. et al. (1997a) Targeted drug delivery in gynaecology: the first uterine pass effect. Hum. Reprod., 12, 1073-1079.
17. Bulletti, C., de Ziegler, D., Giacomucci, E. et al. (1997b) Vaginal drug delivery: the first uterine pass effect. Ann. N.Y. Acad. Sci., 26, 285-290.
18. Buvat, J., Marcolin, G., Guittard, C. et al. (1990) Luteal support after luteinizing hormone-releasing hormone agonist for in vitro fertilization: superiority of human chorionic gonadotropin over oral progesterone. Fertil. Steril., 53, 490-494.
19. Carbone, J.P., Brent, R.L. (1993) Genital and nongenital teratogenesis of prenatal progestogen therapy: the effects of 17 alpha-hydroxyprogesterone caproate on embryonic and fetal development and endochondral ossification in the C57B1/6J mouse. Am. J. Obstet. Gynecol., 169, 1292-1298.
20. Casanas-Roux, F.C., Nisolle, M., Marbaix, E (1996) Morphometric, immunohistological and three-dimensional evaluation of the endometrium of menopausal women treated by oestrogen + Crinone, a new slow-release vaginal progesterone. Hum. Reprod., 11, 357-363.
21. Chakmakjian, Z.H. and Zachariah, N.Y. (1987) Bioavailability of progesterone with different modes of administration. J. Reprod. Med., 32, 443-448.
22. Check, J.H., Rankin, A. and Teichman, M. (1986) The risk of fetal anomalies as a result of progesterone therapy during pregnancy. Fertil. Steril., 45, 575-577.
23. Cicinelli, E., Fanelli, F., Ragno, G. et al. (1991) Progesterone administration by nasal spray. Fertil. Steril., 56, 139-141.
24. Claman, P., Domingo, M. and Leader, A. (1992) Luteal phase support in in-vitro fertilization using gonadotrophin releasing hormone analogue before ovarian stimulation: a prospective randomized study of human chorionic gonadotrophin versus i.m. progesterone. Hum. Reprod., 7, 487-489.
25. Corson, S.L., Batzer, F.R., Gocial, B. et al. (1993) The luteal phase after ovulation induction with human menopausal gonadotropin and one versus two doses of a gonadotropin-releasing hormone agonist. Fertil. Steril., 59, 1251-6.
26. Critchley, H.O., Buckley, C.H. and Anderson, D.C. (1990) Experience with a 'physiological' steroid replacement regimen for the establishment of a receptive endometrium in women with premature ovarian failure. Br. J. Obstet. Gynaecol., 97, 804-810.
27. Cunha, G.R., Taguchi, O., Sugimura, Y. et al. (1988) Absence of teratogenic effects of progesterone on the developing genital tract of the human female fetus. Hum. Pathol., 19, 77-783.
28. Daya, S. (1988) Efficacy of progesterone support in the luteal phase following in-vitro fertilization and embryo transfer: meta-analysis of clinical trials. Hum. Reprod., 3, 731-734.
29. Devroey, P, Palermo, G, Bourgain, C. et al. (1989) Progesterone administration in patients with absent ovaries. Int. J. Fertil., 34, 188-193.
30. de Ziegler, D., Bergeron, C., Cornel, C. et al. (1992) Effects of luteal estradiol on the secretory transformation of human endometrium and plasma gonadotropins. J. Clin. Endocrinol. Metab., 74, 322-331.
31. de Ziegler, D., Fanchin, R., Massonneau, M. et al. (1994) Hormonal control of endometrial receptivity. The egg donation model and controlled ovarian hyperstimulation. Ann. N.Y. Acad. Sci., 30, 209-220.
32. de Ziegler, D., Seidler, L., Scharer, E. et al. (1995) Administration non orale de la progestérone: expériences et avenir de la voie transvaginale. Schweiz Rundsch. Med. Prax., 84, 127-133.
33. Diedrich, K., Diedrich, C., Santos, E. et al. (1994) Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum. Reprod., 9, 788-791.
34. Ditkoff, E.C., Cassidenti, D.L., Paulson, R.J. et al. (1991) The gonadotropin-releasing hormone antagonist (Na1-Glu) acutely blocks the luteinizing hormone surge but allows for resumption of folliculogenesis in normal women. Am. J. Obstet. Gynecol., 165, 1811-1817.
35. Eibs, H.G., Spielmann, H., Hagele, M. (1982) Teratogenic effects of cyproterone acetate and medroxyprogesterone treatment during the pre-and postimplantation period of mouse embryos. I. Teratology, 25, 27-36.
36. Fanchin, R., de Ziegler, D., Bergeron, C. et al. (1997) Transvaginal administration of progesterone : Dose-response data support a first uterine pass effect. Obstet. Gynecol., 90, 396-401.
37. Felberbaum, R., Reissmann, T., Kupker, W. et al. (1996) Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin-releasing hormone (GnRH)-antagonist Cetrorelix at different dosages. J. Assist. Reprod. Genet.. 13, 216-222.
38. Frydman, R., Testart, J., Giacomini, P. et al. (1982) Hormonal and histological study of the luteal phase in women following aspiration of the preovulatory follicle. Fertil. Steril., 38, 312-317.
39. Frydman, R., Cornel, C., de Ziegler, D. et al. (1991) Prevention of premature luteinizing hormone and progesterone rise with a gonadotropin-releasing hormone antagonist, Nal-Glu, in controlled ovarian hyperstimulation. Fertil. Steril., 56, 923-927.
40. Garcia, J., Jones, G.S., Acosta, A.A. et al. (1981) Corpus luteum function after follicle aspiration for oocyte retrieval. Fertil. Steril., 36, 565-572.
41. Garcia, J.E., Acosta, A.A., Hsiu, J.G. et al. (1984) Advanced endometrial maturation after ovulation induction with human menopausal gonadotropin/human chorionic gonadotropin for in vitro fertilization. Fertil. Steril., 41, 31-35.
42. Ghosh, D. and Sengupta, J. (1998) Recent developments in endocrinology and paracrinology of blastocyst implantation in the primate. Hum. Reprod. Update, 4, 153-68.
43. Gibbons, W.E., Toner, J.P., Hamacher, P. et al. (1998) Experience with a novel vaginal progesterone preparation in a donor oocyte program. Fertil. Steril., 69, 96-101.
44. Ginsburg, K.A. (1992) Luteal phase defect. Etiology, diagnosis, and management. Endocrinol. Metab. Clin. N. Am., 21, 85-104.
45. Golan, A., Herman, A., Soffer, Y. et al. (1993) Human chorionic gonadotrophin is a better luteal support than progesterone in ultrashort gonadotrophin-releasing hormone agonist/menotrophin in-vitro fertilization cycles. Hum. Reprod., 8, 1372-1375.
46. Hargove, J.T., Maxson, W.A. and Wentz, A.C. (1989) Absorption of oral progesterone is influenced by vehicle and particle size. Am. J. Obstet. Gynecol., 161, 948-951.
47. Hendrickx, A.G., Korte, R., Leuschner, F. et al. (1987a) Embryotoxicity of sex steroidal hormones in nonhuman primates: II. Hydroxyprogesterone caproate, estradiol valerate. Teratology, 35, 129-136.
48. Hendrickx, A.G., Korte, R., Leuschner, F. et al. (1987b) Embryotoxicity of sex steroidal hormone combinations in nonhuman primates: I. Norethisterone acetate + ethinylestradiol and progesterone + estradiol benzoate (Macaca mulatta, Macaca fascicularis, and Papio cynocephalus). Teratology, 35, 119-127.
49. v is expressed on human luteinizing granulosa cells during corpus luteum formation, and its expression is enhanced by human chorionic gonadotrophin in vitro. Mol. Hum. Reprod., 3, 979-84.
50. Jones, G.S. (1991) Luteal phase defect: a review of pathophysiology. Curr. Opin. Obstet. Gynecol., 3, 641-648.
51. Jordan, J., Craig, K., Clifton, D.K. et al. (1994) Luteal phase defect: the sensitivity and specificity of diagnostic methods in common clinical use. Fertil. Steril., 62, 54-62.
52. Kerin, J.F., Broom, T.J., Ralph, M.M. et al. (1981) Human luteal phase function following oocyte aspiration from the immediately preovular graafian follicle of spontaneous ovular cycles. Br. J. Obstet. Gynaecol., 88, 1021-1028.
53. Kuhl, H. (1990) Pharmacokinetics of oestrogens and progestogens. Maturitas, 12, 171-197.
54. Lammer, E.J., Cordero, J.F. (1986) Exogenous sex hormone exposure and the risk for major malformations. J. Am. Med. Assoc., 13, 3128-3132.
55. Lammer, E.J., Cordero, J.F. and Khoury, M.J. (1986) Exogenous sex hormone exposure and the risk for VACTERL association. Teratology, 34, 165-169.
56. Lanzone, A., Fulghesu, A.M., Villa, P. et al. (1994) Gonadotropin-releasing hormone agonist versus human chorionic gonadotropin as a trigger of ovulation in polycystic ovarian disease gonadotropin hyperstimulated cycles. Fertil. Steril., 62, 35-41.
57. Larsson-Cohn, U, Fahraeus, L. Wallentin, L. et al. (1981) Lipoprotein changes may be minimized by proper composition of a combined oral contraceptive. Fertil. Steril., 35, 172-179.
58. Leeton, J., Trounson, A. and Jessup, D. (1985) Support of the luteal phase in in vitro fertilization programs: results of a controlled trial with intramuscular Proluton. J. In Vitro Fertil. Embryo Transfer, 2, 166-169.
59. Lenton, E.A., Sulaiman, R., Sobowale, O. et al. (1982) The human menstrual cycle: plasma concentrations of prolactin, LH, FSH, oestradiol and progesterone in conceiving and nonconceiving women. J. Reprod. Fertil., 65, 131-139.
60. Martinez-Frias, M.L., Rodriguez-Pinilla, E., Bermejo, E. et al. (1998) Prenatal exposure to sex hormones: a case-control study. Teratology, 57, 8-12.
61. Maxson, W.S. and Hargrove, J.T. (1985) Bioavailability of oral micronized progesterone. Fertil. Steril., 44, 622-626.
62. Miles, R.A., Paulson, R.J., Loho, R.A. et al. (1994) Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil. Steril., 62, 485-490.
63. Mores, N., Krsmanovic, L.Z. and Catt, K.J. (1996) Activation of LH receptors expressed in GnRH neurons stimulates cyclic AMP production and inhibits pulsatile neuropeptide release. Endocrinology, 137, 5731-5734.
64. Nader, S., Berkowitz, A.S., Ochs, D. et al. (1988) Luteal-phase support in stimulated cycles in an in vitro fertilization/embryo transfer program: progesterone versus human chorionic gonadotropin. J. In Vitro Fertil. Embryo Transfer, 5, 81-84.
65. Nahoul, K., Dehennin, L. and Scholler, R (1987) Radioimmunoassay of plasma progesterone after oral administration of micronized progesterone. J. Steroid Biochem., 26, 241-249.
66. Nahoul, K., Dehennin, L., Jondet, M. et al. (1993) Profiles of plasma oestrogens, progesterone and their metabolites after oral or vaginal administration of estradiol or progesterone. Maturitas, 16, 185-202.
67. Nikkanen, V., Kresanov, I., Makinen, J. et al. (1992) The effect of luteal support with human chorionic gonadotrophin or progesterone on the daily progesterone profile after different types of ovarian stimulation. Hum. Reprod., 7, 333-336.
68. Nora, J.J. and Nora, A.H. (1973) Birth defects and oral contraception. Lancet, i, 941-942.
69. Nora, J.J., Nora, A.H., Blu, J. et al. (1978) Exogenous progestogen and oestrogen implicated in birth defects. J. Am. Med. Assoc., 240, 837-843.
70. Norman, T.R., Morse, C.A. and Dennerstein, L. (1991) Comparative bioavailability of orally and vaginally administered progesterone. Fertil. Steril., 56, 1034-1039.
71. Olivennes, F., Fanchin, R., Bouchard, P. et al. (1995) Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in-vitro fertilization cycles: a pilot study. Hum. Reprod., 10, 1382-1386.
72. Penarrubia, J., Balasch, J., Fabregues, F. et al. (1998) Human chorionic gonadotrophin luteal support overcomes luteal phase inadequacy after gonadotrophin-releasing hormone agonist-induced ovulation in gonadotrophin-stimulated cycles. Hum. Reprod., 13, 3315-8.
73. Polson, D.W., Rogers, P.A., Krapez, J.A. et al. (1992) Vaginal progesterone as luteal phase support in an IVF/GIFT programme. Eur. J. Obstet. Gynecol. Reprod. Biol., 46, 35-38.
74. Pouly, J.L., Bassil, S., Frydman, R. et al. (1997) Support de la phase lutéale par la progestérone vaginale: étude comparative avec la progestérone micronisée per os. Contracept-Fertil-Sex., 25, 596-601.
75. Resseguie, L.J., Hick, J.F., Bruen, J.A. et al. (1985) Congenital malformations among offspring exposed in utero to progestins, Olmsted County, Minesota, 1936-1974. Fertil. Steril., 43, 514-519.
76. Ross, D., Cooper, A.J., Pryse-Davies, J. et al. (1997) Randomized, double-blind, dose-ranging study of the endometrial effects of a vaginal progesterone gel in oestrogen-treated postmenopausal women. Am. J. Obstet. Gynecol., 177, 937-941.
77. Rothman, K.J., Fyler, D.C., Goldblatt, A. et al. (1979) Exogenous hormones and other drug exposures of children with congenital heart disease. Am. J. Epidemiol., 109, 433-439.
78. Simón, J.A., Robinson, D.E., Andrews, M.C. et al. (1993) The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone. Fertil. Steril., 60, 26-33.
79. Smith, E.M., Anthony, F.W., Gadd, S.C. et al. (1989) Trial of support treatment with human chorionic gonadotrophin in the luteal phase after treatment with buserelin and human menopausal gonadotrophin in women taking part in an in vitro fertilisation programme. Br. Med. J., 298, 1483-1486.
80. Smitz, J., Devroey, P., Camus, M. et al. (1988) The luteal phase and early pregnancy after combined GnRH-agonist/HMG treatment for superovulation in IVF or GIFT. Hum. Reprod., 3, 585-590.
81. Smitz, J., Devroey, P., Faguer, B. et al. (1992a) A prospective randomized comparison of intramuscular or intravaginal natural progesterone as a luteal phase and early pregnancy supplement. Hum. Reprod., 7, 168-175.
82. Smitz, J., Erard, P., Camus, M. et al. (1992b) Pituitary gonadotrophin secretory capacity during the luteal phase in superovulation using GnRH-agonists and HMG in a desensitization or flare-up protocol. Hum. Reprod., 7, 1225-1229.
83. Smitz, J., Bourgain, C., Van Waesberghe, L. et al. (1993) A prospective randomized study on oestradiol valerate supplementation in addition to intravaginal micronized progesterone in buserelin and HMG induced superovulation. Hum. Reprod., 8, 40-45.
84. Soliman, S., Daya, S., Collins, J. et al. (1994) The role of luteal phase support in infertility treatment: a meta-analysis of randomized trials. Fertil. Steril., 61, 1068-1076.
85. Srivastava, R.K., Luu-The, V., Marrone, B.L. et al. (1994) Suppression of luteal steroidogenesis by an LHRH antagonist (Nal-Lys antagonist: antide) in vitro during early pregnancy in the rat. J. Mol. Endocrinol., 13, 87-94.
86. Steege, J.F., Rupp, S.L, Stout, A.L. et al. (1986) Bioavailability of nasally administered progesterone. Fertil. Steril., 46, 727-729.
87. Stovall, D.W., Van Voorhis, B.J., Mattingly, K.L. et al. (1996) The effectiveness of sublingual progesterone administration during cryopreserved embryo transfer cycles: results of a matched follow-up study. Fertil. Steril., 65, 986-991.
88. Trounson, A., Howlett, D., Rogers, P. et al. (1986) The effect of progesterone supplementation around the time of oocyte recovery in patients superovulated for in vitro fertilization. Fertil. Steril., 45, 532-535.
89. Van Steirteghem, A.C., Smitz, J., Camus, M. et al. (1988) The luteal phase after in-vitro fertilization and related procedures. Hum. Reprod., 3, 161-164.
90. Yovich, J.L., McColm, S.C., Yovich, J.M. et al. (1985) Early luteal serum progesterone concentrations are higher in pregnancy cycles. Fertil. Steril., 44, 185-189.